CMS RBCS · Imaging · Nuclear

Nuclear — codes without an RBCS family

95 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CMS's RBCS classification leaves these codes at the subcategory level — no family is assigned. We list them; we don't invent a family.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Nuclear imaging A9575 Injection, gadoterate meglumine, 0.1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2014 — first year this code appears in Part B claims

National scale 104.52M services · est. ▲ 14.3% YoY · 337,457 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 53.45M observed fee-for-service services

See the national market for A9575 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9585 Injection, gadobutrol, 0.1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 42.76M services · est. ▲ 9.3% YoY · 245,399 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 20.73M observed fee-for-service services

See the national market for A9585 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9579 Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 1.40M services · est. ▼ 3.8% YoY · 40,315 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 664,794 observed fee-for-service services

See the national market for A9579 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9577 Injection, gadobenate dimeglumine (multihance), per ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 723,554 services · est. ▼ 19.3% YoY · 23,594 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 350,918 observed fee-for-service services

See the national market for A9577 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9576 Injection, gadoteridol, (prohance multipack), per ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 508,976 services · est. ▼ 7.4% YoY · 16,973 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 254,995 observed fee-for-service services

See the national market for A9576 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9578 Injection, gadobenate dimeglumine (multihance multipack), per ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 194,538 services · est. ▲ 35.4% YoY · 6,132 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 94,541 observed fee-for-service services

See the national market for A9578 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9587 Gallium ga-68, dotatate, diagnostic, 0.1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 149,271 services · est. ▲ 28.0% YoY · 1,697 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 72,253 observed fee-for-service services

See the national market for A9587 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9581 Injection, gadoxetate disodium, 1 ml CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 127,727 services · est. ▲ 16.3% YoY · 5,902 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 61,488 observed fee-for-service services

See the national market for A9581 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9608 Flotufolastat f 18, diagnostic, 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2024 — first year this code appears in Part B claims

National scale 25,394 services · est. · 1,974 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 12,375 observed fee-for-service services

See the national market for A9608 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A4648 Tissue marker, implantable, any type, each CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 22,180 services · est. ▲ 6.4% YoY · 4,364 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 11,385 observed fee-for-service services

See the national market for A4648 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging Q9969 Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 20,214 services · est. ▲ 6.6% YoY · 6,195 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,893 observed fee-for-service services

See the national market for Q9969 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9586 Florbetapir f18, diagnostic, per study dose, up to 10 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 18,928 services · est. ▲ 2419.0% YoY · 9,285 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 9,301 observed fee-for-service services

See the national market for A9586 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9584 Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 15,146 services · est. ▲ 13.8% YoY · 7,362 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 7,373 observed fee-for-service services

See the national market for A9584 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9505 Thallium tl-201 thallous chloride, diagnostic, per millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 11,701 services · est. ▼ 19.9% YoY · 1,830 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,836 observed fee-for-service services

See the national market for A9505 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging Q9983 Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 11,253 services · est. ▲ 1494.7% YoY · 5,935 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 5,944 observed fee-for-service services

See the national market for Q9983 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging Q9982 Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2016 — first year this code appears in Part B claims

National scale 5,327 services · est. · 2,467 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 2,469 observed fee-for-service services

See the national market for Q9982 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9526 Nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 3,955 services · est. · 997 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,831 observed fee-for-service services

See the national market for A9526 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9592 Copper cu-64, dotatate, diagnostic, 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 3,430 services · est. · 419 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 1,656 observed fee-for-service services

See the national market for A9592 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9516 Iodine i-123 sodium iodide, diagnostic, per 100 microcuries, up to 999 microcuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 995 services · est. ▼ 19.5% YoY · 267 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 486 observed fee-for-service services

See the national market for A9516 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9699 Radiopharmaceutical, therapeutic, not otherwise classified CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 797 services · est. · 108 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 432 observed fee-for-service services

See the national market for A9699 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9554 Iodine i-125 sodium iothalamate, diagnostic, per study dose, up to 10 microcuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 575 services · est. ▼ 23.4% YoY · 323 FFS beneficiary-episodes (CY2021, all-Medicare estimate) — 327 observed fee-for-service services

See the national market for A9554 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9558 Xenon xe-133 gas, diagnostic, per 10 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 379 services · est. ▼ 2.1% YoY · 78 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 189 observed fee-for-service services

See the national market for A9558 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A4641 Radiopharmaceutical, diagnostic, not otherwise classified CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 317 services · est. ▼ 31.5% YoY · 153 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 158 observed fee-for-service services

See the national market for A4641 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9531 Iodine i-131 sodium iodide, diagnostic, per microcurie (up to 100 microcuries) CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 281 services · est. ▲ 15.1% YoY · 81 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 140 observed fee-for-service services

See the national market for A9531 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9528 Iodine i-131 sodium iodide capsule(s), diagnostic, per millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 176 services · est. ▼ 55.5% YoY · 33 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 88 observed fee-for-service services

See the national market for A9528 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9548 Indium in-111 pentetate, diagnostic, per 0.5 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 88 services · est. · 53 FFS beneficiary-episodes (CY2020, all-Medicare estimate) — 53 observed fee-for-service services

See the national market for A9548 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9591 Fluoroestradiol f 18, diagnostic, 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2023 — first year this code appears in Part B claims

National scale 58 services · est. ▼ 70.5% YoY · 12 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 29 observed fee-for-service services

See the national market for A9591 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9515 Choline c-11, diagnostic, per study dose up to 20 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2018 — first year this code appears in Part B claims

National scale 48 services · est. ▼ 83.3% YoY · 26 FFS beneficiary-episodes (CY2022, all-Medicare estimate) — 26 observed fee-for-service services

See the national market for A9515 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9570 Indium in-111 labeled autologous white blood cells, diagnostic, per study dose CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 21 services · est. · 11 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 11 observed fee-for-service services

See the national market for A9570 → ranked groups · states · 12-yr trend

66 more CPT-coded procedures — shown with a trial or subscription, under AMA licensing.